source
- Cytokinetics aims for broader Myqorzo approval next year after supportive trial dataCytokinetics reported new data on its cardiac therapy Myqorzo, presented at a European scientific meeting. The results reinforce the drug’s efficacy in a specific heart muscle disorder. The compan…
- FDA sends warning to Alar over misleading claims about investigational depression drugThe U.S. Food and Drug Administration’s Office of Prescription Drug Promotion sent an untitled warning letter to Alar Pharmaceuticals. The agency says Alar’s promotional materials for ALA-3000, an…